BDA-366

Research use only, not for human use.

A potent, selective Bcl2 BH4 domain antagonist with Ki of 3.3 nM; shows no affinity for other Bcl2 family members, including Bcl-XL, Mcl-1, or Bfl-1/A1.

A potent, selective Bcl2 BH4 domain antagonist with Ki of 3.3 nM; shows no affinity for other Bcl2 family members, including Bcl-XL, Mcl-1, or Bfl-1/A1; induces apoptotic cell death in a Bax-dependent manner, and induces calcium (Ca2+) release via inhibition of Bcl2/IP3R interaction; potently represses lung cancer in vivo, and induces Bcl2 conformational change in tumor tissues.

NSC-639366;NSC639366;BDA366

Angiogenesis

Bcl-2

Bcl-2

Cancer

——

1909226-00-1

423.50

C24H29N3O4

>98% (HPLC)

——

CCN(CC)CC(CNC1=C2C(=C(C=C1)NCC3CO3)C(=O)C4=CC=CC=C4C2=O)O

1-(((S)-3-(diethylamino)-2-hydroxypropyl)amino)-4-((((S)-oxiran-2-yl)methyl)amino)anthracene-9,10-dione

(-20℃)

With Ice Pack

≥ 2 years